OVERVIEW
Tenosynovial Giant Cell Tumor Diagnosis and Systemic Therapy: Interprofessional Strategies for Enhanced Outcomes is organized by i3 Health.
Dates Available:
July 14, 2026 - July 13, 2027
Statement of Need:
Tenosynovial giant cell tumor (TGCT) is a rare, locally aggressive neoplasm of the synovium, bursae, and tendon sheaths that can lead to chronic pain, recurrent joint swelling, progressive functional impairment, and irreversible joint destruction. Localized TGCT can often be effectively managed with surgical excision; however, diffuse TGCT is associated with a substantial risk of recurrence after surgery. Recent advances have led to the approval of systemic therapies targeting the CSF-1/CSF1R signaling pathway for patients with symptomatic TGCT that is not amenable to surgery. These CSF1R inhibitors have demonstrated meaningful improvements in tumor response, range of motion, physical function, and patient-reported outcomes. To individualize treatment decisions in a rapidly changing therapeutic landscape, clinicians must navigate important differences in toxicity profiles and monitoring requirements to optimize long-term outcomes (Stacchiotti et al, 2023; Assi et al, 2025). In this Virtual Tumor Board activity, Brian E. Brigman, MD, PhD; Jason L. Hornick, MD, PhD; Robert A. Lefkowitz, MD; and Richard F. Riedel, MD, explore interprofessional strategies to equip the multidisciplinary team to accurately diagnose localized and diffuse TGCT, integrate evolving consensus recommendations, and individualize treatment decisions for enhanced outcomes in TGCT.
Learning Objectives:
Upon completion of this activity, participants should be able to
- Identify clinical, pathologic, and radiologic features of localized and diffuse TGCT to support a timely and accurate diagnosis
- Apply current evidence and expert guidance to select appropriate treatment strategies for patients with TGCT
- Implement risk mitigation and monitoring strategies to reduce complications associated with systemic therapies for TGCT
- Recognize and manage common and serious CSF1R inhibitor–related adverse events
ACCREDITATION & CREDITS
TARGET AUDIENCE
PhysicianNursingPharmacistPhysician AssistantSPECIALITIES
OncologyPathologyAbdominal RadiologyOrthopedicsTERMS & CONDITIONS
DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES
i3 Health endorses the standards of the ACCME that require everyone in a position to control the content of a CME activity to disclose all financial relationships with ineligible companies that are related to the content of the CME activity. CME activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.
A conflict of interest is created when an individual has an opportunity to affect CME content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.
i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.
Relevant financial relationships exist between the following individuals and ineligible companies:Relevant financial relationships exist between the following individuals and ineligible companies:
The i3 Health planners, reviewers, and managers have nothing to disclose.
Brian E. Brigman, MD, PhD, discloses that he has served on an advisory board or panel for Daiichi Sankyo, Deciphera, and Musculoskeletal Transplant Foundation; and that he has received grants/research support from Musculoskeletal Transplant Foundation.
Jason L. Hornick, MD, PhD, has no relevant financial relationships to disclose.
Robert Lefkowitz, MD, has no relevant financial relationships to disclose.
Richard F. Riedel, MD, discloses that he has served on an advisory board or panel for AADi, Adaptimmune, Bayer, Blueprint, Boehringer Ingelheim, Cogent, Daiichi Sankyo, Deciphera, EMD Serono, GlaxoSmithKline, Ipsen, NanoCarrier, Recordati, Replimmune, and SpringWorks; that he has served as a consultant for GlaxoSmithKline and SpringWorks; and that he has received grants/research support from AADi, Adaptimmune, AROG, Ayala, BioAtla, Blueprint, Cogent, Daiichi Sankyo, Deciphera, GlaxoSmithKline, InhibRx, Intensity Therapeutics, Kura Oncology, NanoCarrier, Oncternal, PTC Therapeutics, SARC, Servier, SpringWorks, SynOx Therapeutics, Tracon, Trillium, and US WorldMeds.
i3 Health has mitigated all relevant financial relationships.
INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, participants must attend the scheduled activity and submit a completed evaluation at the end of the activity.
COMMERCIAL SUPPORT
Supported by an independent educational grant from Daiichi Sankyo.
CONTACT INFORMATION
Technical queries or questions regarding activity credit should be directed to i3 Health at support@emedevents.com.
Download eMedEvents Mobile App
Track your CE certificates and CME requirements anytime, anywhere.
RELATED ONLINE COURSES
Webcast
Dentistry
2.5 CE Credits
By eMedEd, Inc.
Nov 28, 2024 - Nov 08, 2028 | Text-Based CME
State required course for Connecticut ...
2 Contact Hour
Quick Links